2型糖尿病伴左室舒张功能不全患者使用比索洛尔后B型尿钠肽与左室舒张功能的变化研究

被引：7

作者：

杨燕华

黄庆宁

叶键烽

黄虔

机构：

[1] 广东省东莞市人民医院心内科

来源：

中国全科医学 | 2013年 / 16卷 / 37期

关键词：

糖尿病,2型; 左室舒张功能不全; 比索洛尔; B型尿钠肽;

D O I：

暂无

中图分类号：

R587.2 [糖尿病性昏迷及其他并发症];

学科分类号：

1002 ; 100201 ;

摘要：

目的探讨2型糖尿病伴左室舒张功能不全患者使用比索洛尔后B型尿钠肽(BNP)与左室舒张功能的变化。方法选取于2011年8—10月在东莞市人民医院就诊的2型糖尿病伴左室舒张功能不全患者100例(BNP≥100 pg/ml,心率>70次/min,35～75岁),采用随机数字表分为对照组和治疗组各50例。两组患者采用一致的降糖方案,在此基础上,治疗组给予比索洛尔口服,起始剂量为2.5～5.0 mg,每周调整一次剂量,2周后每月调整一次剂量,每次调整剂量为1.25～2.50 mg,使治疗组目标心率达到60～65次/min,随访1年。比较两组患者的BNP、左室射血分数(EF)、左房室瓣舒张早期血流峰值与舒张晚期血流峰值的比值(E/A)、左房容积指数(LAVI)以及心血管事件发生率。结果随访1年后,两组患者的BNP、E/A、EF间比较差异均无统计学意义(P>0.05);治疗组的LAVI和心率〔分别为(17.9±2.6)ml/m2和(62±4)次/min〕较对照组〔分别为(20.0±4.6)ml/m2和(81±7)次/min〕下降,差异均有统计学意义(P<0.05)。随访1年后,对照组出现心力衰竭症状2例,治疗组没有患者出现心力衰竭;对照组有3例新发高血压,治疗组有1例;两组各有1例出现心肌缺血;两组均无死亡病例,差异均无统计学意义(P>0.05)。结论 2型糖尿病伴左室舒张功能不全患者使用比索洛尔1年后,LAVI明显下降,左室舒张功能得到改善。

引用

页码：3683 / 3685

页数：3

共 15 条

[1]

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart. McMurray John J V,Adamopoulos Stamatis,Anker Stefan D,Auricchio Angelo,B?hm Michael,Dickstein Kenneth,Falk Volkmar,Filippatos Gerasimos,Fonseca Candida,Gomez-Sanchez Miguel Angel,Jaarsma Tiny,K?ber Lars,Lip Gregory Y H,Maggioni Aldo Pietro,P.

[2]

Pre-clinical diabetic cardiomyopathy: prevalence, screening, and outcome. Stephanie Kiencke,Rolf Handschin,Ruth von Dahlen. EUROPEAN JOURNAL OF HEART FAILURE . 2010

[3]

Association and prognostic impact of heart rate and micro- albuminuria in patients with type 2 diabetes and cardiovascular disease: results from the PROactive trial. Pfister Roman,Erdmann Erland,Schneider Christian Alfons. Journal of atherosclerosis and thrombosis . 2010

[4]

Rate Control with Ivabradine[J] . Neeraj Parakh,Balram Bhargava. &nbspAmerican Journal of Cardiovascular Drugs . 2011 (1)

[5]

[Diabetic cardiomyopathy: old disease or new entity?]. Seferovi? Petar M,Lali? Nebojsa M,Seferovi? Jelena P,Joti? Aleksandra,Lali? Katarina,Risti? Arsen D,Simeunovi? Dejan,Radovanovi? Gorica,Vujisi?-Tesi? Bosiljka,Ostaji? Miodrag U. Srpski arhiv za celokupno lekarstvo . 2007

[6]

Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Kim Fox,Ian Ford,P Gabriel Steg,Michal Tendera,Michele Robertson,Roberto Ferrari,on behalf of the BEAUTIFUL investigators. The Lancet . 2008

[7]

Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies[J] . C Voulgari,Dimitrios Papadogiannis,Nicholas Tentolouris. &nbspVascular Health and Risk Management . 2010 (defa)

[8] Heart Rate Predicts Mortality in Patients With Heart Failure and Preserved Systolic Function [J].

Kapoor, John R. ;

Heidenreich, Paul A. .

JOURNAL OF CARDIAC FAILURE, 2010, 16 (10) :806-811

[9]

Relationship between natriuretic peptides and echocardiography parameters in patients with poorly regulated type 2 diabetes[J] . Magnus Dencker,Mozhgan Dorkhan,Martin Stagmo. &nbspVascular Health and Risk Management . 2010 (defa)

[10]

Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography[J] . Sherif F. Nagueh,Christopher P. Appleton,Thierry C. Gillebert,Paolo N. Marino,Jae K. Oh,Otto A. Smiseth,Alan D. Waggoner,Frank A. Flachskampf,Patricia A. Pellikka,Arturo Evangelista. &nbspJournal of the American Society of Echocardiography . 2009 (2)

← 1 2 →